Frontage Holdings Corporation (HKG:1521)

Market Cap	2.31B +3.8%
Revenue (ttm)	1.99B -2.7%
Net Income	30.10M -37.1%
EPS	0.01 -35.4%
Shares Out	2.03B
PE Ratio	76.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	142,200
Open	n/a
Previous Close	1.140
Day's Range	n/a
52-Week Range	0.900 - 1.870
Beta	0.33
RSI	58.43
Earnings Date	Mar 30, 2026

About Frontage Holdings

Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 1,540
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1521

Financial Performance

In 2024, Frontage Holdings's revenue was $254.91 million, a decrease of -1.90% compared to the previous year's $259.86 million. Earnings were $791,000, a decrease of -92.68%.

Financial numbers in USD